Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ardelyx, Inc. stock logo
ARDX
Ardelyx
$5.56
+3.0%
$6.14
$3.49
$8.40
$1.33B0.583.04 million shs4.58 million shs
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
$37.58
-3.8%
$44.20
$15.80
$94.90
$2.67B-1.35606,978 shs515,294 shs
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$69.22
-6.4%
$57.14
$23.30
$80.50
$4.60B2.231.44 million shs2.47 million shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for June 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ardelyx, Inc. stock logo
ARDX
Ardelyx
+2.96%-7.95%-21.69%-10.18%+50.68%
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
-3.79%-4.47%-7.98%-34.90%+70.82%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-6.37%+3.51%+16.28%+47.46%+127.40%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ardelyx, Inc. stock logo
ARDX
Ardelyx
$5.56
+3.0%
$6.14
$3.49
$8.40
$1.33B0.583.04 million shs4.58 million shs
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
$37.58
-3.8%
$44.20
$15.80
$94.90
$2.67B-1.35606,978 shs515,294 shs
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$69.22
-6.4%
$57.14
$23.30
$80.50
$4.60B2.231.44 million shs2.47 million shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for June 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ardelyx, Inc. stock logo
ARDX
Ardelyx
+2.96%-7.95%-21.69%-10.18%+50.68%
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
-3.79%-4.47%-7.98%-34.90%+70.82%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-6.37%+3.51%+16.28%+47.46%+127.40%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ardelyx, Inc. stock logo
ARDX
Ardelyx
2.90
Moderate Buy$15.70182.37% Upside
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
2.89
Moderate Buy$109.25190.71% Upside
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
2.75
Moderate Buy$58.00-16.21% Downside

Current Analyst Ratings Breakdown

Latest TWST, GPCR, and ARDX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/22/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Set Price Target$80.00
5/5/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Boost Price TargetBuy$55.00 ➝ $60.00
5/5/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Boost Price TargetOutperform$50.00 ➝ $65.00
5/5/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
UpgradeMarket PerformOutperform$70.00
5/4/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Boost Price TargetOverweight$55.00 ➝ $65.00
4/27/2026
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
Initiated CoverageBuy$101.00
4/27/2026
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
UpgradeStrong-Buy$101.00
4/21/2026
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
Reiterated RatingSell (D-)
4/20/2026
Ardelyx, Inc. stock logo
ARDX
Ardelyx
Reiterated RatingSell (D-)
4/14/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Boost Price TargetOverweight$50.00 ➝ $55.00
3/30/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Boost Price TargetBuy$50.00 ➝ $55.00
(Data available from 6/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ardelyx, Inc. stock logo
ARDX
Ardelyx
$407.32M3.37N/AN/A$0.69 per share8.06
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
N/AN/AN/AN/A$24.99 per shareN/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$376.57M11.45N/AN/A$7.84 per share8.83
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ardelyx, Inc. stock logo
ARDX
Ardelyx
-$61.60M-$0.23N/A10.49N/A-13.58%-38.11%-11.85%8/3/2026 (Estimated)
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
-$141.20M-$0.87N/AN/AN/AN/A-24.91%-23.67%8/6/2026 (Estimated)
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$77.67M-$1.33N/AN/AN/A-19.85%-26.73%-19.15%8/3/2026 (Estimated)

Latest TWST, GPCR, and ARDX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2026Q1 2026
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
-$0.39-$0.35+$0.04-$0.35$11.11 millionN/A
5/4/2026Q2 2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$0.49-$0.71-$0.22-$0.71$107.64 million$110.72 million
4/30/2026Q1 2026
Ardelyx, Inc. stock logo
ARDX
Ardelyx
-$0.13-$0.15-$0.02-$0.15$92.78 million$94.47 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Ardelyx, Inc. stock logo
ARDX
Ardelyx
N/AN/AN/AN/AN/A
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
N/AN/AN/AN/AN/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ardelyx, Inc. stock logo
ARDX
Ardelyx
1.37
3.49
3.28
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
N/A
26.16
26.16
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
0.03
2.70
2.42

Institutional Ownership

CompanyInstitutional Ownership
Ardelyx, Inc. stock logo
ARDX
Ardelyx
58.92%
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
91.78%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/A

Insider Ownership

CompanyInsider Ownership
Ardelyx, Inc. stock logo
ARDX
Ardelyx
5.30%
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
5.50%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
3.08%
CompanyEmployeesShares OutstandingFree FloatOptionable
Ardelyx, Inc. stock logo
ARDX
Ardelyx
90247.03 million233.94 millionOptionable
Structure Therapeutics Inc. Sponsored ADR stock logo
GPCR
Structure Therapeutics
13671.08 million67.17 millionOptionable
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
99062.27 million60.35 millionOptionable

Recent News About These Companies

Twist Bioscience (TWST) Gets a Buy from Guggenheim

New MarketBeat Followers Over Time

Media Sentiment Over Time

Ardelyx stock logo

Ardelyx NASDAQ:ARDX

$5.56 +0.16 (+2.96%)
Closing price 06/5/2026 04:00 PM Eastern
Extended Trading
$5.57 +0.01 (+0.18%)
As of 06/5/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Structure Therapeutics stock logo

Structure Therapeutics NASDAQ:GPCR

$37.58 -1.48 (-3.79%)
Closing price 06/5/2026 04:00 PM Eastern
Extended Trading
$38.64 +1.06 (+2.82%)
As of 06/5/2026 06:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Twist Bioscience stock logo

Twist Bioscience NASDAQ:TWST

$69.22 -4.71 (-6.37%)
Closing price 06/5/2026 04:00 PM Eastern
Extended Trading
$70.68 +1.46 (+2.11%)
As of 06/5/2026 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.